发现两种新型免疫表位并开发基于肽的结节病免疫检测方法
研究通过T7噬菌体展示库从结节病cDNA中鉴定出cofilin μ和chain A两种表位,并建立直接肽ELISA检测血清表位特异性IgG。在386例受试者中,cofilin μ IgG模型平均灵敏度0.97、特异度0.9,chain A模型分别为0.9和0.83,联合两项生物标志物可提高AUC及诊断性能,为结节病提供新型免疫检测。
要点
- cofilin μ IgG模型诊断结节病灵敏度0.97、特异度0.9。
- chain A IgG模型灵敏度0.9、特异度0.83。
- 联合两种表位可改善AUC及诊断性能。
核心结论
- 研究提供了一种针对结节病的新型免疫检测方法,并发现两种新抗原可用于生物特异性药物研发和结节病特异性模型构建。
研究设计与样本
- 研究基于结节病cDNA构建高通量T7噬菌体展示库,经克隆测序和同源搜索鉴定出cofilin μ和chain A两种表位。
- 化学合成两种免疫表位并制备兔多克隆抗体,经标准化后建立直接肽ELISA。
- 检测386例受试者血清表位特异性IgG,包括健康对照100例、结节病三个队列186例、肺结核70例和肺癌30例。
主要发现
- cofilin μ IgG模型的平均灵敏度、特异度、阳性预测值和阴性预测值分别为0.97、0.9、0.9和0.96。
- chain A IgG抗体的平均灵敏度、特异度、阳性预测值和阴性预测值分别为0.9、0.83、0.84和0.9。
- 联合两种生物标志物提高了曲线下面积、灵敏度、特异度及阳性和阴性预测值。
关键数值与推荐
- cofilin μ IgG模型:灵敏度0.97、特异度0.9、阳性预测值0.9、阴性预测值0.96。
- chain A IgG模型:灵敏度0.9、特异度0.83、阳性预测值0.84、阴性预测值0.9。
临床怎么用
- 该表位特异性IgG免疫检测可用于辅助区分结节病与其他呼吸系统疾病,联合两种标志物可能提升诊断性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Sarcoidosis is a systemic granulomatous disorder associated with hypergammaglobulinemia and the presence of autoantibodies. The specific antigens initiating granulomatous inflammation in sarcoidosis are unknown, and there is no specific test available to diagnose sarcoidosis. To discover novel sarcoidosis antigens, we developed a high-throughput T7 phage display library derived from the sarcoidosis cDNA and identified numerous clones differentiating sarcoidosis from other respiratory diseases. After clone sequencing and a homology search, we identified two epitopes (cofilin μ and chain A) that specifically bind to serum IgGs of patients with sarcoidosis. Objectives: To develop and validate an epitope-specific IgG-based immunoassay specific for sarcoidosis. Methods: We chemically synthesized both immunoepitopes (cofilin μ and chain A) and generated rabbit polyclonal antibodies against both neoantigens. After extensive standardization, we developed a direct peptide ELISA and measured epitope-specific IgG in the sera of 386 subjects, including healthy control subjects (n = 100), three sarcoidosis cohorts (n = 186), pulmonary tuberculosis (n = 70), and lung cancer (n = 30). Measurements and Main Results: To develop a model to classify sarcoidosis distinctly from other groups, data were analyzed using fivefold cross-validation when adjusting for confounders. The cofilin μ IgG model yielded a mean sensitivity, specificity, and positive and negative predictive value of 0.97, 0.9, 0.9, and 0.96, respectively. Those same measures for chain A IgG antibody were 0.9, 0.83, 0.84, and 0.9, respectively. Combining both biomarkers improved the area under the curve, sensitivity, specificity, and positive and negative predictive value. Conclusions: These results provide a novel immunoassay for sarcoidosis. The discovery of two neoantigens facilitates the development of biospecific drug discovery and the sarcoidosis-specific model.
引用
- Peng C, Talreja J, Steinbauer B, et al. Discovery of Two Novel Immunoepitopes and Development of a Peptide-based Sarcoidosis Immunoassay. Am J Respir Crit Care Med. 2024. PMID: 38385694. doi:10.1164/rccm.202306-1054OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。